1. Show article details.

    Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference

    GlobeNewswire – 8:34 AM ET 10/19/2021

    Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its head of Research and Development, Arun Upadhyay, PhD, will present pre-clinical data demonstrating how the company’s second modifier gene therapy candidate, OCU410, could potent...

  2. Show article details.

    BRIEF-Ocugen Inc Announces Inducement Grants Under Nasdaq Listing Rule

    Reuters – 9:44 AM ET 10/16/2021

    Ocugen Inc (OCGN): * Ocugen Inc (OCGN). ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635. * Ocugen Inc (OCGN) - STOCK OPTIONS HAVE A TEN-YEAR TERM AND HAVE AN EXERCISE PRICE OF $8.66 PER SHARE, WHICH IS CLOSING PRICE OF OCUGEN'S COMMON STOCK ON GRANT DATE Source text for Eikon: Further company coverage:

  3. Show article details.

    Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 9:42 AM ET 10/16/2021

    Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen (OCGN) approved the grant of stock options to purchase an aggregate of 48,800 shares of its common stock and restricted stock unit...

  4. Show article details.

    OCUGEN INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN

    Business Wire – 10:50 PM ET 10/08/2021

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF continues to investigate Ocugen, Inc. (OCGN). On June 10, 2021, the Company disclosed that it would pursue a “biologics license application” with the U.S. Food and Drug Administration for its COVID-19 vaccine candidate/product rather than the Emergency Use Authoriza...

  5. Show article details.

    BRIEF-Ocugen Inc - Entered Into A Development And Commercial Supply Agreement With Bharat Biotech International

    Reuters – 4:23 PM ET 10/04/2021

    Ocugen Inc (OCGN): * Ocugen Inc (OCGN) - ENTERED INTO A DEVELOPMENT AND COMMERCIAL SUPPLY AGREEMENT WITH BHARAT BIOTECH INTERNATIONAL. * Ocugen Inc (OCGN) - BHARAT BIOTECH WILL EXCLUSIVELY MANUFACTURE AND SUPPLY THE COMPANY WITH ITS REQUIREMENTS OF COVAXIN CLINICAL TRIAL MATERIALS.

  6. Show article details.

    OCUGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN

    PR Newswire – 10:50 PM ET 09/24/2021

    NEW ORLEANS, Sept. 24, 2021  Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF continues to investigate Ocugen, Inc. (OCGN).  . On June 10, 2021, the Company disclosed that it would pursue a "biologics license application" with the U.S. Food and Drug Administration for its COVID-19 vaccine candidate/product rather...

  7. Show article details.

    Ocugen, Inc. to Participate in Fireside Chat at the Cantor Virtual Global Healthcare Conference

    GlobeNewswire – 4:08 PM ET 09/23/2021

    Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that its Chairman, CEO, and Co-Founder, Dr. Shankar Musunuri, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8 a.m. Eastern Time.

  8. Show article details.

    Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:52 PM ET 09/17/2021

    Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen (OCGN) approved the grant of stock options to purchase an aggregate of 137,250 shares of its common stock and restricted stock uni...

  9. Show article details.

    BRIEF-Ocugen Inc Provided An Update With Respect To Impact Of Co'S Regulatory Submission To Health Canada For Covaxin

    Reuters – 5:40 PM ET 09/15/2021

    Ocugen Inc (OCGN): * Ocugen Inc (OCGN) - PROVIDED AN UPDATE WITH RESPECT TO IMPACT OF CO'S REGULATORY SUBMISSION TO HEALTH CANADA FOR COVAXIN. * OCUGEN (OCGN) - CO ADVISED THAT EXPIRATION OF INTERIM ORDER ON SEPT 16, WILL NOT IMPACT CO'S NEW DRUG SUBMISSION. * OCUGEN (OCGN) - CO ADVISED THAT HEALTH CANADA'S REVIEW WILL CONTINUE WITHOUT CHANGE TO TIMING OF REVIEW Further company coverage:

  10. Show article details.

    OCUGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ocugen, Inc. - OCGN

    Business Wire – 10:50 PM ET 09/10/2021

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF has commenced an investigation into Ocugen, Inc. (OCGN). On June 10, 2021, the Company disclosed that it would pursue a “biologics license application” with the U.S. Food and Drug Administration for its COVID-19 vaccine candidate/product rather than the Emergency Us...

  11. Show article details.

    Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences

    GlobeNewswire – 5:22 PM ET 09/07/2021

    Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in Citi’s 16th Annual BioPharma Virtual Conference being held on September 8-10, 2021 and at the H.C. Wainwright Global Investment Conference being held on September ...

  12. Show article details.

    Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:34 PM ET 08/20/2021

    Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen (OCGN) approved the grant of stock options to purchase an aggregate of 84,000 shares of its common stock and restricted stock unit...

  13. Show article details.

    BRIEF-Ocugen Provides Business Update And Second Quarter 2021 Financial Results

    Reuters – 7:51 AM ET 08/06/2021

    Ocugen Inc (OCGN): * Q2 LOSS PER SHARE $0.13. * Q2 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES DATA. * ON TRACK TO INITIATE OUR FIRST GENE THERAPY CLINICAL TRIAL FOR OCU400 IN LATTER PART OF 2021. * CURRENTLY ALSO EVALUATING OPTIONS TO COMMENCE OCU400 CLINICAL TRIALS IN EUROPE IN 2022.

  14. Show article details.

    Ocugen Provides Business Update and Second Quarter 2021 Financial Results

    GlobeNewswire – 7:32 AM ET 08/06/2021

            Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., Aug. 06, 2021 -- Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today reported second quarter 2021 financial results along with a general business update.

  15. Show article details.

    SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocugen, Inc. of Class Action Lawsuit and Upcoming Deadline - OCGN

    PR Newswire – 10:25 PM ET 08/03/2021

    NEW YORK, Aug. 3, 2021  Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. (OCGN) and certain of its officers. If you are a shareholder who purchased or otherwise acquired Ocugen (OCGN) securities during the Class Period, you have until August 17, 2021 to ask the Court to appoint you as Lead Plaintiff for the class.

  16. Show article details.

    Ocugen to Host Conference Call on Friday, August 6 at 8:30 a.m. ET to Discuss Second Quarter 2021 Financial Results and Provide Business Update

    GlobeNewswire – 8:45 AM ET 07/30/2021

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its second quarter 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, August 6, 2021.

  17. Show article details.

    Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:59 PM ET 07/16/2021

    Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen (OCGN) approved the grant of stock options to purchase an aggregate of 150,750 shares of its common stock and restricted stock uni...

  18. Show article details.

    Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™

    GlobeNewswire – 7:34 AM ET 07/15/2021

    Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it had initiated a rolling submission to Health Canada for COVAXIN™, the company’s candidate vaccine against COVID-19, which it is co-developing with Bharat Biotech Internation...

  19. Show article details.

    Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease

    GlobeNewswire – 5:42 PM ET 07/02/2021

    MALVERN, Pa., and HYDERABAD, India, July 02, 2021 -- Ocugen (OCGN), Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its co-development partner, Bharat Biotech, shared positive results of its Phase 3 study of COVAXIN™, a whole virion in...

  20. Show article details.

    Ocugen, Inc. Announces Ken Inchausti as Head, Investor Relations & Communications

    GlobeNewswire – 9:12 AM ET 06/21/2021

    Ocugen, Inc. (OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Ken Inchausti has joined the company as Head, Investor Relations & Communications.

Page:

Today's and Upcoming Events

  • Nov
    04

    OCGN to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    06

    OCGN announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.